A health care provider is participating in a clinical trial of a ...

[Capo]

A health care provider is participating in a clinical trial of a new drug. Which statement should the health care provider communicate to the participant in this type of pharmacoeconomic analy-sis?
 
  a. The clinical trial is designed to provide incentives for competitors to lower the costs of a specific drug.
  b. The clinical trial is designed to allow open participation by anyone wishing to try the new drug.
  c. The clinical trial is designed to determine how to provide the drug at the lowest possible cost.
  d. The clinical trial is designed to evaluate the safety and efficacy of a specific drug.

Question 2

A cost-of-illness analysis is conducted for diabetes mellitus. Which of the following variables would be expected to be included in such a study?
 
  a. Comparison of costs with the assumption that the outcomes of all interventions are equal
  b. Client preferences regarding treatment options and life-years saved
  c. Direct costs of medical services and indirect costs from loss of productivity due to illness
  d. The outcome of treatment in terms of a natural health unit (reduction in serum glucose level)

[nhea]

Answer to Question 1

ANS: D
The majority of pharmacoeconomic analyses are piggy-backed onto clinical trials evaluating the efficacy and safety of a specific treatment or intervention. The Food and Drug Administration (FDA) requests that pharmacoeconomic analyses be attached to clinical trials. Economic data are collected as part of the clinical trial and used to determine the cost-effectiveness of the treatment under study.

Answer to Question 2

ANS: C
A cost-of-illness analysis measures both direct and indirect costs associated with an illness. The other choices refer to cost-minimization, cost-utility, and cost-effectiveness analyses, respective-ly.

[Capo]

Great answer, keep it coming

[mcabuhat]

TYSM